Cardiovascular disease remains the leading cause of mortality among women globally, accounting for approximately one in every three deaths annually, yet the medical community continues to grapple with a persistent gap in diagnosis, treatment, and research representation. This disparity was the focal point of a high-level panel discussion held at the MedTech Conference in Boston, where industry leaders, clinicians, and innovators gathered to outline the systemic changes required to achieve equity in heart health. Moderated by Colby Holtshouse, CEO of May Health, the session moved beyond identifying the problem to pinpointing specific market opportunities and scientific frontiers where the medical technology industry must pivot to save female lives.
The urgency of the discussion is underscored by decades of data suggesting that women’s cardiovascular symptoms often diverge from the traditional "Hollywood heart attack" model of crushing chest pain. Instead, women frequently present with fatigue, shortness of breath, nausea, or pain in the jaw and back—symptoms that are often misattributed to anxiety or non-cardiac issues. The panelists argued that the path forward requires a fundamental shift in how the industry approaches inflammation, patient advocacy, clinical trial design, and data collection.
The Role of Inflammation and Autoimmune Factors
A primary area identified for scientific and commercial expansion is the study of inflammation and its disproportionate impact on female physiology. Dr. Kathleen Jordan, Chief Medical Officer at Midi Health, a virtual care clinic specializing in menopause, emphasized that the medical community still views many female-specific inflammatory responses as a "black box."
"Women have more inflammation; they have more autoimmune disease," Dr. Jordan noted during the session. She highlighted the biological reality that systemic inflammation is intrinsically linked to higher rates of cardiovascular disease, as well as secondary conditions such as dementia and various cancers. In women, the transition through menopause serves as a critical window of cardiovascular risk, as the decline in estrogen—a hormone with anti-inflammatory properties—can lead to rapid changes in vascular health.
Current research indicates that nearly 80% of autoimmune disease cases occur in women, and these conditions, such as lupus and rheumatoid arthritis, are known independent risk factors for premature heart disease. Dr. Jordan called for a surge in research and development (R&D) to better understand these pathways, suggesting that diagnostic tools capable of tracking inflammatory markers specifically in the context of the female hormonal cycle could represent a significant market opportunity for medtech developers.
The Advocacy Crisis: Moving Beyond Clinical Dismissal
The panel also addressed the human element of the diagnostic gap, specifically the necessity of listening to female patients. Sarah Huoh, Corporate Vice President of Public Affairs at Edwards Lifesciences, shared a poignant case study that illustrated the systemic barriers women face even when they have a known medical history.
Huoh recounted the experience of a woman named Leslie, a survivor of childhood cancer. Due to the radiation exposure required to treat her cancer years prior, Leslie eventually developed heart valve disease—a common long-term side effect of thoracic radiation. Despite her history and deteriorating health, Leslie faced a grueling multi-year struggle to secure the necessary surgical intervention, as her symptoms were repeatedly overlooked or deemed too complex for standard protocols.
"She had to advocate and fight for herself in this day and age to get the treatment that she needed," Huoh told the audience. She challenged the industry to reconsider why patients are forced into such "agony" to receive life-saving care. Huoh argued that the medtech sector must better integrate the "bedside experience" into product development, ensuring that clinicians are equipped with the tools and the training to recognize and validate the lived experiences of female patients.
Dismantling the "Afterthought" Mentality in Clinical Design
For decades, the "male as default" model has dominated clinical research. Alicia Chong Rodriguez, founder of Bloomer Tech, asserted that the industry must move past the era where women are treated as an afterthought in the design of medical solutions. Bloomer Tech is currently at the forefront of this shift, developing "smart" clothing integrated with advanced sensors to collect cardiovascular data tailored to the female body.
Historically, clinical trials have underrepresented women, leading to a lack of data on how medical devices and pharmaceuticals interact with female-specific biology. Rodriguez pointed out that even basic diagnostic equipment, such as the standard 12-lead ECG, was originally designed based on male torso proportions and does not always account for breast tissue or different heart positioning in women.
"It should come front and center that we’re building for female patients," Rodriguez stated. By designing for women from the ground up—rather than adapting male-centric products—the industry can unlock more accurate diagnostic capabilities and improve patient adherence. The panel suggested that the next generation of cardiovascular tech must be "female-first," incorporating factors like smaller anatomy, hormonal fluctuations, and different disease manifestations such as Microvascular Dysfunction, which is more common in women than the obstructive coronary artery disease typically seen in men.
Data Enrichment and the Economic Imperative for Investment
The discussion concluded with a call for a radical restructuring of how data is gathered and valued. Dr. Laura Mauri, Senior Vice President and Chief Scientific and Medical Officer at Medtronic, argued that to correct historical imbalances, the industry must "enrich the data" by intentionally overrepresenting women in new studies.
Dr. Mauri highlighted that this need is even more acute for women of color, who face the highest rates of cardiovascular mortality but the lowest levels of representation in clinical research. "From an investment standpoint, why wouldn’t we double down on an area that is undertreated and underserved?" Dr. Mauri asked.
The economic case for this investment is compelling. According to a 2024 report by the McKinsey Health Institute and the World Economic Forum, closing the gender health gap could add $1 trillion to the global economy annually by 2040. In cardiovascular care specifically, more accurate diagnostics and earlier interventions would significantly reduce the burden of chronic care and emergency hospitalizations.
Historical Context: A Legacy of Exclusion
The challenges discussed in Boston are rooted in a long history of medical exclusion. It was not until the NIH Revitalization Act of 1993 that women and minorities were legally required to be included in clinical research funded by the National Institutes of Health. Prior to this, researchers often excluded women of childbearing age due to concerns over hormonal fluctuations or potential pregnancy, leading to a "knowledge gap" that persists today.
While progress has been made, recent studies show that women still make up less than 40% of participants in clinical trials for new cardiovascular devices and drugs. The panelists at the MedTech Conference emphasized that this is no longer just a social or ethical issue, but a scientific failure that limits the efficacy of modern medicine.
Implications for the MedTech Industry
The insights shared by the panelists suggest a roadmap for the future of the medtech industry. Companies that prioritize female-specific data and anatomical design are likely to find a massive, untapped market. Key areas for development include:
- AI-Driven Diagnostics: Algorithms trained on female-specific datasets to recognize non-traditional symptoms of myocardial infarction and heart failure.
- Wearable Monitoring: Devices like those from Bloomer Tech that provide continuous, long-term monitoring of heart health in a way that fits into women’s daily lives and accounts for physiological differences.
- Specialized Interventional Tools: Smaller stents, catheters, and valves designed for the typically smaller arterial structures found in women.
- Integrated Care Platforms: Virtual clinics like Midi Health that bridge the gap between endocrine health (menopause) and cardiovascular risk management.
As the MedTech Conference concluded, the consensus among the experts was clear: the industry can no longer afford to treat half the population as a "special interest" group. Addressing women’s cardiovascular health requires a comprehensive overhaul of the R&D pipeline, from the initial hypothesis in the lab to the final clinical application at the bedside. By listening to women, investing in their specific biological data, and refusing to let them remain an "afterthought," the medtech sector has the potential to turn the tide on the world’s leading killer of women.
